Literature DB >> 8119424

Management of the anticoagulated patient for ophthalmic surgery.

P McCormack1, P R Simcock, A B Tullo.   

Abstract

The outcome of 50 surgical procedures in 41 patients who were anticoagulated at the time of surgery were reviewed to determine whether anticoagulation was associated with an increase in ophthalmic morbidity. Twenty-seven patients were receiving warfarin and 14 patients nicoumalone. The International Normalised Ratio (INR) was determined immediately prior to surgery and ranged from 1.1 to 4.9. Thirty-nine operations were performed under local anaesthetic and 11 under general anaesthetic. Thirty-three patients had extracapsular cataract extractions with posterior chamber lens implantation. No major haemorrhagic complications were associated with the local anaesthetic or the surgical procedure. Patients on anticoagulation therapy are at risk of life-threatening complications if their anticoagulation is stopped or reduced. This study demonstrates that most ophthalmic surgical procedures can be safely performed whilst the patient is therapeutically anticoagulated.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8119424     DOI: 10.1038/eye.1993.174

Source DB:  PubMed          Journal:  Eye (Lond)        ISSN: 0950-222X            Impact factor:   3.775


  4 in total

1.  Aspirin is a hazard for vitreoretinal surgery.

Authors:  C J Elaxel; R K Blach
Journal:  Br J Ophthalmol       Date:  1996-05       Impact factor: 4.638

Review 2.  Perioperative management of the chronically anticoagulated patient.

Authors:  J A Heit
Journal:  J Thromb Thrombolysis       Date:  2001-09       Impact factor: 2.300

3.  Maintenance of warfarin anticoagulation for patients undergoing vitreoretinal surgery.

Authors:  Pouya N Dayani; M Gilbert Grand
Journal:  Trans Am Ophthalmol Soc       Date:  2006

4.  Perioperative Management of Anticoagulants in Ocular Surgeries.

Authors:  Xu He; Alexander F Chen; Rajinder S Nirwan; Jayanth Sridhar; Ajay E Kuriyan
Journal:  Int Ophthalmol Clin       Date:  2020
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.